Correlation of subepithelial haze and refractive regression 1 month after photorefractive keratectomy for myopia.
OBJECTIVE
To relate myopic regression after photorefractive keratectomy (PRK) to subepithelial haze at the first postoperative month.


METHODS
One hundred nineteen eyes of 119 patients underwent excimer laser PRK for treatment of myopia up to -8.00 D. Eyes were examined at 1, 3, 6, 9, and 12 months after surgery. All eyes received fluorometholone 0.1% for the first 5 postoperative months in a tapered dose. Dexamethasone 0.1% qid for 1 month was prescribed to all eyes with a spherical equivalent refraction less than plano, followed by an augmented dose of fluorometholone 0.1%. Eyes with myopia greater than -0.75 D at 12 months, as well as those that had received dexamethasone at any postoperative interval--regardless of refractive outcome--were considered to be regressed. Eyes that regressed and those that did not regress were compared statistically (Chi-squared statistical criterion with Yate's correction) regarding haze grade.


RESULTS
Forty-seven percent (56 of 119) of eyes regressed. In 89.28% (50 of 56) of eyes, subepithelial haze grade was 1 to 2, and in 10.71% (6 of 56), subepithelial haze was graded 0 to 0.5 at 1 month. Fifty-three percent of eyes (63 of 119) did not regress and in all, subepithelial haze was graded 0 to 0.5 at the first month. The correlation between regression and haze grade 1 or more at the first postoperative month was statistically significant (P<.001).


CONCLUSIONS
Mild to marked subepithelial haze (grade 1 to 2) at the first postoperative month after PRK for myopia is strongly related to regression of initial refractive effect and increasing myopia.
Siganos
D S
DS
Department of Ophthalmology, University of Crete, Greece. siganos@med.uch.gr
Katsanevaki
V J
VJ
Pallikaris
I G
IG
D000328:Adult; D003315:Cornea / Q000503:physiopathology / Q000601:surgery*; D003318:Corneal Opacity / Q000209:etiology / Q000503:physiopathology*; D019781:Corneal Topography; D003907:Dexamethasone / Q000008:administration & dosage / Q000627:therapeutic use; D019573:Epithelium, Corneal / Q000503:physiopathology*; D005260:Female; D005469:Fluorometholone / Q000008:administration & dosage / Q000627:therapeutic use; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D054018:Lasers, Excimer; D008297:Male; D009216:Myopia / Q000503:physiopathology / Q000601:surgery*; D009883:Ophthalmic Solutions; D018903:Photorefractive Keratectomy / Q000009:adverse effects*; D012029:Refraction, Ocular; D012189:Retrospective Studies; D016896:Treatment Outcome; D014792:Visual Acuity
D005938:Glucocorticoids; D009883:Ophthalmic Solutions; D003907:Dexamethasone; D005469:Fluorometholone